Neues Brustkrebsmedikament erfordert sorgfältiges Blutzuckermonitoring
Studientitel, Nr., Akronym Alpelisib (BYL719) + Exemestan +/- Everolimus bei Patientinnen mit fortgeschrittenem Mammakarzinom P
Cureus | Alpelisib-Induced Diabetic Ketoacidosis
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer - ScienceDirect
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications | Breast Cancer Research | Full Text
Mechanism of Action | PIQRAY® (alpelisib) tablets | HCP
Daily Medication Pearl: Alpelisib (Piqray)
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Le | OTT
Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors - Ando - 2019 - Cancer Science - Wiley Online Library
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
PDF) Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
Patient-Centered Diabetes Care of Cancer Patients | SpringerLink
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
Leitfaden zur Verringerung von Arzneimittel- und Anwendungsrisiken – Ärzte Piqray® (Alpelisib)
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data - Oncology Nurse Advisor
Pharmacist Management of Alpelisib-Associated Hyperglycemia
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Trial to Assess Alpelisib in Combination with Fulvestrant in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer | Future Oncology
14 days Ambulatory Glucose Profile following start of alpelisib... | Download Scientific Diagram
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer | Future Oncology
Detecting and Managing Drug-Induced Diabetes
Novartis: US-Zulassung für Alpelisib | APOTHEKE ADHOC
